Clinics I work with
Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy.
TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
Journal for immunotherapy of cancer
Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
Clinical science (London, England : 1979)
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prosta...
Incidence and severity of treatment-emergent adverse events
Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Ce...
TIICs will be analyzed in pre- and post-pembrolizumab-based treatment tumor specimens. The proportion of participants with a >=2-fold increase (from pre- to post-treatment) in the number of TIICs will be calculated.
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in ...
Dose limiting toxicity (DLT) is defined as protocol-defined adverse events that occur within 28 days following infusion of Neo-TCR-P1 administered as a single agent without or with IL-2, or in combination with nivolumab.
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumor...
The proportion of participants who show clinical benefit, defined as complete response (CR), partial response (PR), or stable disease (SD) for ≥ 6 months as best response by RECIST v1.1